PDHA2

Across TCGA pan-cancer cohorts, PDHA2 Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated PDHA2 data layer compared with 12 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PDHA2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PDHA2 expression acts as an unfavorable survival marker, although some lineages such as LUSC and SKCM show a favorable association.

HNSC, COAD, and ESCA are the cancer types where PDHA2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.187	0.610	.002	15	view →
COAD	OS	Median	IV	0.082	0.659	<.001	13	view →
ESCA	OS	Median	II,III,IV	0.104	0.926	<.001	12	view →
LIHC	OS	Median	All	0.264	0.709	.027	12	view →
TGCT	DFS	Median	All	0.146	0.801	.020	6	view →
ACC	OS	Median	All	0.118	0.624	.038	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUSC	DFS	Median	All	0.934	0.751	.039	5	view →
SKCM	DFS	Median	II,III,IV	0.810	0.542	.043	3	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

PDHA2–HNSC (OS)

Open the HNSC breakdown →